2013 Archived Content

SC12 First-in-Human Study and Risk Mitigation Strategy for Biologics 

 

Target Audience:


The session will be useful for basic and clinical scientists, clinical pharmacologists, physicians, pharmacists and other healthcare professionals who are interested in early drug development and want to increase their understanding of first in human study starting dose estimation, dose escalation scheme, and risk evaluation and mitigation strategy (REMS) for biologics.

Presentation outlines:
 

  • To overview the basic concepts and study designs for early drug development including Phase I First in Human (FIH) Single Ascending Dose (SAD), Food Effect (EF), Multiple Ascending Dose (MAD) and Phase IIa Proof of Concept (POC) studies.
  • Using Tegenero first in human (FIH) incident as a case study, to review the evolving process of biologic FIH starting dose estimation from No Observed Adverse Effect Level (NOAEL) to Minimum Anticipated Biological Effect level (MABEL) approach. 
  • FIH study in Oncology will be reviewed separately due to its uniqueness and significant unmet medical needs.
  • To introduce the Biologic FIH Study Risk Evaluation and Mitigation Strategy (REMS).
     
 

<<Back to Short Courses 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 Brochure cover 

Premier Sponsors:

Abbott Molecular 

 

Elsevier  


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large